Skip to content
DataLookout
Menu

NCT07593222

Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 5 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Start date changed from estimate of Sep 1, 2026 to Oct 1, 2026
    • Secondary endpoints: details revised at 5 of 5 entries
    • Site details revised
    • Publications: details revised at 3 of 3 entries
  2. Notable Start date: Jul 1, 2026 to Sep 1, 2026v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

P30 TMS-Evoked Potential (TEP) Amplitude
Timeframe: From baseline to approximately 10 minutes after cTBS administration, assessed at each of four study visits completed over a minimum of 3 to 6 weeks

Secondary (5)

Additional TEP Component Amplitudes
16-item Quick Inventory of Depressive Symptomatology (QIDS-SR16)
Patient Health Questionnaire-9 (PHQ-9)
7-item Generalized Anxiety Disorder scale (GAD-7)
24-item Behavior and Symptom Identification Scale (BASIS-24)

Arms and interventions

Sham iTBS + PlaceboSham comparator

Placebo TMS and placebo drug

iTBS + PlaceboPlacebo comparator

Active TMS and placebo drug

iTBS + D-cycloserineExperimental

Active TMS and active medication

iTBS + dextromethorphanExperimental

Active TMS and active medication

Devices: Sham iTBS, TMS

Drugs: D-cycloserine, Dextromethophan, Placebo

Sites

1 site in 1 country

  • McLean HospitalBelmont, Massachusetts, United States